1. Yin, Wenjun, He, Pingkaiqi, Zou, Zhihao, Lu, Jianming, Zhong, Weide. 2024. SLC15A2 Serves as a Novel Prognostic Biomarker and Target for Prostate Cancer. In Anticancer research, 45, 153-172. doi:10.21873/anticanres.17402. https://pubmed.ncbi.nlm.nih.gov/39740843/
2. Zeng, Hao, Chen, Naicheng, Chen, Fang, Wang, Junping, Hu, Mengjia. 2024. Exercise alleviates hematopoietic stem cell injury following radiation via the carnosine/Slc15a2-p53 axis. In Cell communication and signaling : CCS, 22, 582. doi:10.1186/s12964-024-01959-2. https://pubmed.ncbi.nlm.nih.gov/39627813/
3. Lee, Yeon-Su, Kim, Bo Hyun, Kim, Byung Chul, Bhak, Jong, Park, Joong-Won. . SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma. In Oncotarget, 6, 16449-60. doi:. https://pubmed.ncbi.nlm.nih.gov/25965825/
4. Cai, Liang-Liang, Huang, Wen-Qing, Su, Zhi-Ying, Zhang, Wei, Tzeng, Chi-Meng. 2017. Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population. In Scientific reports, 7, 17379. doi:10.1038/s41598-017-17731-1. https://pubmed.ncbi.nlm.nih.gov/29234073/